ADMA Biologics Inc (ADMA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ADMA Biologics Inc (ADMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9860
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ADMA Biologics Inc (ADMA Biologics) is an integrated biopharmaceutical and specialty immunoglobulin company that develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company develops RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin, derived from human plasma containing naturally occurring polyclonal antibodies to treat Primary Immune Deficiency Disease. ADMA Biologics’ target treatment areas include bacterial infections, respiratory syncytial virus and primary immune deficiency diseases. It also operates bio centers which carry out plasma collection and offer blood plasma to manufacture the company’s products. ADMA Biologics is headquartered in Ramsey, New Jersey, the US.

ADMA Biologics Inc (ADMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
ADMA Biologics Acquires Certain Assets from Biotest Pharma 11
Venture Financing 13
ADMA Biologics Secures USD20 Million from Oxford Finance 13
Adma Biologics Secures USD5 Million from Hercules 14
ADMA Biologics Secures Venture Funding from Biomark Capital 16
ADMA Plasma Biologics Raises US$17.6 Million In Venture Financing 17
Licensing Agreements 18
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 18
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
Equity Offering 21
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
ADMA Biologics to Raise Funds through Public Offering of Shares 23
ADMA Biologics Raises USD42 Million in Public Offering of Shares 24
ADMA Biologics Plans to Raise Funds through Secondary Offering of Shares 26
ADMA Biologics Raises USD14 Million in Public Offering of Shares 28
ADMA Biologics Raises USD11.2 Million in Public Offering of Shares 30
ADMA Biologics Completes IPO For US$28.5 Million 32
ADMA Biologics Raises USD17.6 Million in Private Placement of Shares 33
Acquisition 35
R&R Acquisition Acquires ADMA Biologics In Reverse Acquisition 35
ADMA Biologics Inc – Key Competitors 36
ADMA Biologics Inc – Key Employees 37
ADMA Biologics Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 10, 2018: ADMA Biologics reports second quarter 2018 financial results 39
May 14, 2018: ADMA Biologics Reports First Quarter 2018 Financial Results 41
Mar 05, 2018: ADMA Biologics Announces Full Year 2017 Financial Results 42
Nov 03, 2017: ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 43
Aug 11, 2017: ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 45
May 12, 2017: ADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results 47
Feb 24, 2017: ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones 48
Legal and Regulatory 49
Jul 26, 2018: Adma Biologics reports successful close-out of its April 2018 FDA compliance inspection 49
Other Significant Developments 50
Jun 27, 2017: ADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders 50
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADMA Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADMA Biologics Acquires Certain Assets from Biotest Pharma 11
ADMA Biologics Secures USD20 Million from Oxford Finance 13
Adma Biologics Secures USD5 Million from Hercules 14
ADMA Biologics Secures Venture Funding from Biomark Capital 16
ADMA Plasma Biologics Raises US$17.6 Million In Venture Financing 17
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 18
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
ADMA Biologics to Raise Funds through Public Offering of Shares 23
ADMA Biologics Raises USD42 Million in Public Offering of Shares 24
ADMA Biologics Plans to Raise Funds through Secondary Offering of Shares 26
ADMA Biologics Raises USD14 Million in Public Offering of Shares 28
ADMA Biologics Raises USD11.2 Million in Public Offering of Shares 30
ADMA Biologics Completes IPO For US$28.5 Million 32
ADMA Biologics Raises USD17.6 Million in Private Placement of Shares 33
R&R Acquisition Acquires ADMA Biologics In Reverse Acquisition 35
ADMA Biologics Inc, Key Competitors 36
ADMA Biologics Inc, Key Employees 37
ADMA Biologics Inc, Subsidiaries 38

List of Figures
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ADMA Biologics Inc (ADMA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Zuivelcooperatie FrieslandCampina UA:企業の戦略的SWOT分析
    Zuivelcooperatie FrieslandCampina UA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Merge Healthcare Incorporated:企業のM&A・事業提携・投資動向
    Merge Healthcare Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merge Healthcare Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Vietnam Electricity-エネルギー分野:企業M&A・提携分析
    Summary Vietnam Electricity (EVN) is an electric utility, which generates, transmits and distributes, and sells energy. It produces power from hydro, coal, oil, and gas sources. The company operates various power plants and electricity generation companies. EVN owns the electricity retailing, transm …
  • ADES International Holding Plc (ADES):企業の財務・戦略的SWOT分析
    ADES International Holding Plc (ADES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Schneider Electric SE:企業のM&A・事業提携・投資動向
    Schneider Electric SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Schneider Electric SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • National Central Cooling Company:企業の戦略・SWOT・財務情報
    National Central Cooling Company - Strategy, SWOT and Corporate Finance Report Summary National Central Cooling Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Enel Generacion Chile SA (ENELGXCH):電力:M&Aディール及び事業提携情報
    Summary Enel Generacion Chile SA (Enel Generacion), formerly Empresa Nacional de Electricidad SA, is a power utility. It generates, distributes and sells electricity, exports natural gas, and provides various energy related products and services. The company produces electricity using hydro, gas, fu …
  • SBM Offshore NV (SBMO)-石油・ガス分野:企業M&A・提携分析
    Summary SBM Offshore N.V. (SBM Offshore) is a floating production solutions provider for offshore oil and gas industry. The company designs supplies, installs and operates Floating Production, Storage and Offloading (FPSO) vessels. The company leases its FPSO vessels to its clients. It also undertak …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Johnson Controls International Plc (JCI):企業の財務・戦略的SWOT分析
    Johnson Controls International Plc (JCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • IntelGenx Corp:企業のM&A・事業提携・投資動向
    IntelGenx Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IntelGenx Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Patterson-UTI Energy Inc (PTEN):企業の財務・戦略的SWOT分析
    Patterson-UTI Energy Inc (PTEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Eppendorf AG-医療機器分野:企業M&A・提携分析
    Summary Eppendorf AG (Eppendorf) is a life science company. The company develops and produces equipment and services for use in laboratory applications such as liquid handling, cell handling, and sample handling. Its product portfolio includes automated pipetting systems, centrifuges, dispensers, mi …
  • Carriage Services Inc (CSV):企業の財務・戦略的SWOT分析
    Summary Carriage Services Inc (Carriage Services) is a provider of professional funeral and cemetery products and services. The company’s operations include funeral homes operation, cemeteries operations, cemetery locations and crematoria, and combined funeral home. It provides funeral home operatio …
  • General Atomics:企業の戦略・SWOT・財務情報
    General Atomics - Strategy, SWOT and Corporate Finance Report Summary General Atomics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Systematic A/S:企業の戦略・SWOT・財務分析
    Systematic A/S - Strategy, SWOT and Corporate Finance Report Summary Systematic A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Duke Energy Indiana LLC:企業の発電所・SWOT分析2018
    Duke Energy Indiana LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Composites Technology Research Malaysia Sdn. Bhd.:企業の戦略・SWOT・財務情報
    Composites Technology Research Malaysia Sdn. Bhd. - Strategy, SWOT and Corporate Finance Report Summary Composites Technology Research Malaysia Sdn. Bhd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • Agile Therapeutics Inc (AGRX):企業の財務・戦略的SWOT分析
    Summary Agile Therapeutics Inc (Agile) is a healthcare company that develops and commercializes prescription contraceptive products for women. The company provides contraceptive patch containing the active ingredients levonorgestrel and ethinyl estradiol and progestin-only birth control patch. Its p …
  • Aqua Bio Technology ASA (ABT):企業の財務・戦略的SWOT分析
    Summary Aqua Bio Technology ASA (ABT) is a biotechnology company that develops, produces and markets new active ingredients. The company’s products comprise Aquabeautine XL and Smids. Its product Aquabeautine XL is derived from the hatching fluid of salmon. ABT’s products are based on research and d …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆